Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan (Q33490031)

27 July 2017

1 reference

title

Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan (English)

1 reference

27 July 2017

Josep Redon

1

1 reference

27 July 2017

Maria Jose Fabia

series ordinal

2

1 reference

27 July 2017

publication date

3 August 2009

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

27 July 2017

published in

1 reference

27 July 2017

volume

10

1 reference

27 July 2017

issue

3

1 reference

27 July 2017

page(s)

147-156

1 reference

2007 Guidelines for the Management of Arterial Hypertension

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Circadian variation in blood pressure: implications for the elderly patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

How important is 24-hour control of blood pressure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Angiotensin II type 1 receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Use of an olmesartan medoxomil-based treatment algorithm for hypertension control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309342735

21 January 2018

Identifiers

DOI

10.1177/1470320309342735

1 reference

27 July 2017

1 reference